Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
19 participants
INTERVENTIONAL
2009-08-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antitumor T Cell Responses in Patients With Bladder Cancer
NCT06334406
Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)
NCT03333356
Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder
NCT03529890
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
NCT04943094
Patient-reported Outcomes in Bladder Cancer
NCT03584659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tumor-boost
Image-guided tumorboost of the bladder cancer.
Radiation boost
Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiation boost
Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unifocal
* TNM stage T2a-4a, N0-1, M0
* unfit for radical cystectomy
Exclusion Criteria
* Multinodular goiter
* Pregnancy
* Breast feeding
* WHO preformance status more than 2
* Iodine allergy
* MRI or CT contrast media allergy
* Bi-lateral hip-prosthesis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jimmi Sondergaard
Role: PRINCIPAL_INVESTIGATOR
The department of Oncology, Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The department of Oncology, Aarhus University Hospital
Aarhus, , Denmark
The department of Oncology, Rigshospitalet
Copenhagen, , Denmark
The department of Oncology, Herlev University Hospital
Herlev, , Denmark
The department of Oncology, Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M-20080210
Identifier Type: -
Identifier Source: secondary_id
CIRRO IP 070109 DaBlaCa-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.